These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8573421)

  • 21. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
    Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
    Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation.
    Marie PJ
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S11-5. PubMed ID: 16735840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats.
    Sakai S; Takeda S; Sugimoto M; Shimizu M; Shimonaka Y; Yogo K; Hashimoto J; Bauss F; Endo K
    Bone; 2015 Dec; 81():449-458. PubMed ID: 26281770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.
    Reitsma PH; Teitelbaum SL; Bijvoet OL; Kahn AJ
    J Clin Invest; 1982 Nov; 70(5):927-33. PubMed ID: 7130396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morphometric evidence that YM175, a bisphosphonate, reduces trabecular bone resorption in ovariectomized dogs with dietary calcium restriction.
    O'uchi N; Nishikawa H; Motoie H; Shikama H
    Jpn J Pharmacol; 1999 Mar; 79(3):397-400. PubMed ID: 10230870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.
    Green JR; Müller K; Jaeggi KA
    J Bone Miner Res; 1994 May; 9(5):745-51. PubMed ID: 8053405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the trabecular rat bone mineral: effect of ovariectomy and bisphosphonate treatment.
    Bohic S; Rey C; Legrand A; Sfihi H; Rohanizadeh R; Martel C; Barbier A; Daculsi G
    Bone; 2000 Apr; 26(4):341-8. PubMed ID: 10719276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bisphosphonate therapy.
    Licata AA
    Am J Med Sci; 1997 Jan; 313(1):17-22. PubMed ID: 9001162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
    Azuma Y; Sato H; Oue Y; Okabe K; Ohta T; Tsuchimoto M; Kiyoki M
    Bone; 1995 Feb; 16(2):235-45. PubMed ID: 7756053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strontium ranelate: a novel mode of action optimizing bone formation and resorption.
    Marie PJ
    Osteoporos Int; 2005 Jan; 16 Suppl 1():S7-10. PubMed ID: 15578159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advantages of concurrent use of anabolic and antiresorptive agents over single use of these agents in increasing trabecular bone volume, connectivity, and biomechanical competence of rat vertebrae.
    Kobayashi S; Shimizu T; Mehdi R; Nawata M; Kojima S; Tsutsumimoto T; Iorio R; Takaoka K
    Bone; 1999 Dec; 25(6):703-12. PubMed ID: 10593416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Possible mechanism of the specific action of bisphosphonates on osteoclasts].
    Udagawa N
    Nihon Rinsho; 2003 Feb; 61(2):207-12. PubMed ID: 12638209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats.
    Lauritzen DB; Balena R; Shea M; Seedor JG; Markatos A; Le HM; Toolan BC; Myers ER; Rodan GA; Hayes WC
    J Bone Miner Res; 1993 Jul; 8(7):871-9. PubMed ID: 8352069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prior administration of vitamin K2 improves the therapeutic effects of zoledronic acid in ovariectomized rats by antagonizing zoledronic acid-induced inhibition of osteoblasts proliferation and mineralization.
    Zhao B; Zhao W; Wang Y; Zhao Z; Zhao C; Wang S; Gao C
    PLoS One; 2018; 13(8):e0202269. PubMed ID: 30125322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of dichloromethylene diphosphonate, a pyrophosphate analog, on bone and bone cell structure in the growing rat.
    Miller SC; Jee WS
    Anat Rec; 1979 Mar; 193(3):439-62. PubMed ID: 154858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strontium ranelate in osteoporosis.
    Reginster JY
    Curr Pharm Des; 2002; 8(21):1907-16. PubMed ID: 12171530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quinoxaline derivative of oleanolic acid inhibits osteoclastic bone resorption and prevents ovariectomy-induced bone loss.
    Zhao Y; Huai Y; Jin J; Geng M; Li JX
    Menopause; 2011 Jun; 18(6):690-7. PubMed ID: 21228726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological effects of tiludronate in horses after long-term immobilization.
    Delguste C; Amory H; Doucet M; Piccot-Crézollet C; Thibaud D; Garnero P; Detilleux J; Lepage OM
    Bone; 2007 Sep; 41(3):414-21. PubMed ID: 17604709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tiludronate therapy for Paget's disease of bone.
    McClung MR; Tou CK; Goldstein NH; Picot C
    Bone; 1995 Nov; 17(5 Suppl):493S-496S. PubMed ID: 8573425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis.
    Reginster JY
    Bone; 1992; 13(5):351-4. PubMed ID: 1419375
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.